What is claimed is:

1. ~~A method for reducing a fat deposit *in vivo*, the method comprising contacting the fat deposit with an effective amount~~ Use of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine in the manufacture of a medicament for reducing a fat deposit in vivo, wherein, the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, the contacting step is carried out by direct injection of the composition into the fat deposit, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and ~~the effective amount of~~ the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

2. The use~~method~~ of claim 1, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

3. The use~~method~~ of claim 2, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

~~4. The method of claim 1, wherein the contacting step is carried out by direct injection of the composition into the fat deposit.~~

~~5. The method of claim 4, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

4~~6~~. The use~~method~~ of claim 1~~5~~, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

5~~7~~. The use~~method~~ of claim 1~~4~~, wherein a volume of 25 µL to 75 µl of the composition is injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

8~~6~~. ~~The method of claim 1, wherein the contacting step is carried out by injection of the composition into an interstitial space adjacent to the fat deposit~~Use of a composition of

latanoprost encapsulated in a liposome in the manufacture of medicament for reducing a fat deposit in vivo, wherein the medicament is to be injected into an interstitial space adjacent to the fat deposit and the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, and the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

79. The usemethod of claim 68, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.

810. The usemethod of claim 79, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

911. The usemethod of claim 68, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

10. Use of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament for reducing a subcutaneous fat deposit in vivo, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the composition reduces a number of adipocytes in the subcutaneous fat deposit by 5% to 90%.

~~12. The method of claim 1, wherein the fat deposit is a subcutaneous fat deposit and the contacting step is carried out by subcutaneous injection of the composition into or adjacent to the subcutaneous fat deposit.~~

~~13. The method of claim 12, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

1114. The usemethod of claim 1013, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

12~~15~~. The use~~method~~ of claim 10~~12~~, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

13~~16~~. ~~A method for~~Use of an effective amount of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament in treating steatoblepharon in a subject, ~~the method comprising identifying a subject in need of treatment for steatoblepharon and injecting~~ wherein the medicament is to be injected ~~-~~into a fat deposit in an eyelid of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, , a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and ~~the effective amount of~~ the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

14~~17~~. The use~~method~~ of claim 13~~16~~, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

15~~18~~. The use~~method~~ of claim 14~~17~~, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

~~19. The method of claim 16, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

16~~20~~. The use~~method~~ of claim 13~~19~~, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

17~~21~~. The use~~method~~ of claim 13~~16~~, wherein a volume of 25 µL to 75 µl of the composition is to be injected for each 0.5 cm^3 to 1.0 cm^3 of the fat deposit.

18~~22~~. Use of an effective amount of a composition of latanoprost encapsulated in a liposome ~~A method for~~in the manufacture of a medicament in treating proptosis in a subject~~,, the method comprising identifying a subject in need of treatment for proptosis~~ wherein the medicament is to be ~~and injecting~~injected into an intraconal space of the subject an effective

amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and ~~the effective amount of~~ the composition reduces a number of adipocytes in the intraconal space by at least 35%.

1923. The use~~method~~ of claim 1822, wherein the proptosis is a result of thyroid-associated orbitopathy.

~~24. The method of claim 23, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

2025. The use~~method~~ of claim 1924, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

2126. The use~~method~~ of claim 1822, wherein the subject suffers from Grave's disease or Hashimoto's thyroiditis.

~~27. The method of claim 26, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

2228. The use ~~method~~ of claim 2127, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

2329. Use of an effective amount of a composition of latanoprost encapsulated in a liposome in the manufacture of a medicament ~~A method~~ for treating obstructive sleep apnea associated with an excess upper airway fat in a subject, ~~the method comprising identifying a subject in need of treatment for obstructive sleep apnea and~~ wherein said medicament is to be injected~~ing~~ into an upper airway fat deposit of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in

the composition is 0.5 mg/mL to 3.0 mg/mL, ~~the effective amount of~~ the composition reduces a number of adipocytes in the upper airway fat deposit by 5% to 90%.

24~~30~~. The use~~method~~ of claim 23~~29~~, wherein the upper airway fat deposit is located in the palate, the tongue, or the pharynx.

25. The use of claim 23, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.

26~~31~~. The use~~method~~ of claim 23~~29~~, wherein the number of adipocytes in the fat deposit is reduced by 10% to 90%.

27~~31~~. The use~~method~~ of claim 26~~30~~, wherein the number of adipocytes in the fat deposit is reduced by 35% to 90%.

~~32. The method of claim 29, wherein a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL.~~

~~33. The method of claim 32, wherein the concentration of latanoprost is 1.0 mg/mL to 2.3 mg/mL.~~